Summary of Key Information:

Reporting Period (Quarter/Year): Quarter ended 30th June, 2026 (Q1 FY27)

Nature of Filing / Announcement: Outcome of Board Meeting - Unaudited Standalone & Consolidated Financial Results under SEBI LODR Regulation 33

Audit Opinion:

Clean Limited Review Report - No modifications or qualifications. The review was conducted in accordance with SRE 2410 by Khurana Sharma & Company, Chartered Accountants (FRN: 010920N).

Auditor’s Comment:

No material misstatements were identified. The financial results include unaudited results of subsidiaries (Adley Formulations Pvt Ltd, Adley Lab Limited, Beta Research Private Limited & Nivian Lifesciences Private Limited) which were not reviewed by their auditors but were furnished by management.

Key Financial Highlights [₹ Crores]:

Consolidated Results:

Revenue from Operations: ₹125.55 crores (25.3% increase YoY from ₹100.20 crores in Q1FY26)

Total Income: ₹127.13 crores

EBITDA (including other income): ₹28.95 crores

EBITDA (excluding other income): ₹27.37 crores (38.9% growth YoY)

EBITDA Margin (including other income): 23.06%

EBITDA Margin (excluding other income): 21.80%

Net Profit: ₹16.48 crores (40.92% growth YoY from ₹11.70 crores in Q1FY26)

Net Profit Margin: 13.1%

EPS: ₹14.78 (Basic and Diluted)

Standalone Results:

Revenue from Operations: ₹93.77 crores

Total Income: ₹96.85 crores

Net Profit: ₹5.93 crores

EPS: ₹5.55 (Basic and Diluted)

Segment-wise Performance:

Branded Oncology: Sales of ₹33.0 Crores, 47% YoY growth driven by improved performance from existing products and new launches.

CMO Business: 41% YoY growth driven by strong customer traction and new launches including proprietary NDDS products. Expected better performance in FY27 with higher realizations in platins.

Exports Business: ₹17.2 Crores in Q1FY27. Expected higher growth for remainder of FY27 as orders accelerate.

Nivian: 45% YoY growth from increased penetration and full quarter performance of new products launched in Q4 FY26.

Corporate Actions:

Not Specified

Other Significant Information:

  • Improved gross margins at 56.6% in Q1FY27 vs 50.4% in Q1FY26 due to favorable sales mix toward branded businesses including Nivian
  • Reduced finance costs due to conversion of CCDs issued in Nov 2024 and converted in May 2026 (Interest cost: ₹0.75 Crores in Q1FY27 vs ₹2.1 Crores in Q1FY26)
  • Vision 2030 targets: Accelerated growth, higher margins, with >80% of turnover from high margin businesses (own branded products and exports)
  • FY27 guidance: 20-25% consolidated growth expected
  • Backward integration in KSMs and advanced intermediates expected to improve operating margins
  • Robust pipeline of NDDS products for launch in FY27 and FY28
  • Focus on being First to Launch/First few to Launch in India for new products

Entities Included in Consolidation:

Adley Formulations Pvt Ltd, Adley Lab Limited, Beta Research Private Limited, Nivian Lifesciences Private Limited